#genfleet - Twitter Hashtag

2 months ago

Insider confidence buying, $SLS #genfleet 3d medicine owes @SellasLife $191 million. @AnsonGroupFunds Bought 4.8 % of #sellas_stock. #gps is the #Regal key.

TadDickson333's tweet photo. Insider confidence buying, $SLS #genfleet 3d medicine owes @SellasLife $191 million. @AnsonGroupFunds
Bought 4.8 % of #sellas_stock. #gps is the #Regal key. https://t.co/9KbwVNtKjx

0

2

1

0

411

Michel Doepke

@doepke_michel

2 months ago

#GenFleet GFH375 Monotherapy Data Presented at #ASCO26: World’s First Dedicated Data of a RAS Inhibitor for Cholangiocarcinoma Show Preliminary Efficacy; Monotherapy Activity Observed together with Prospects for Combinational Regimens in Colorectal Cancer Treatment. $VSTM

doepke_michel's tweet photo. #GenFleet GFH375 Monotherapy Data Presented at #ASCO26: World’s First Dedicated Data of a RAS Inhibitor for Cholangiocarcinoma Show Preliminary Efficacy; Monotherapy Activity Observed together with Prospects for Combinational Regimens in Colorectal Cancer Treatment. $VSTM https://t.co/n3kxPAQZTU

1

8

0

1

4K

Michel Doepke

@doepke_michel

4 months ago

#AACR26: #GenFleet Therapeutics Announces Data of VS-7375/GFH375 from Partner $VSTM Preclinical Studies, Demonstrating Superior Potency, Durable Pathway Control, and Rational Mechanism-supported Combinations for KRAS G12D–Mutant Cancers https://t.co/xE6dQqrRzV

0

18

1

2

9K

Michel Doepke

@doepke_michel

10 months ago

$VSTM #GenFleet

Grainne O'Kane @graokane

10 months ago

GFH375: KRAS G12Di targets both ‘on’ & ‘off’ states #PDAC #ESMO2025 @OncoAlert ➡️68% >|= 2 lines tx ➡️ORR 41%; mPFS 5.6mths ➡️mOS NR; most AEs grade 1/2 ➡️ctDNA - high rates KRAS(not~90%), low tumour suppressor rates

graokane's tweet photo. GFH375: KRAS G12Di targets both ‘on’ & ‘off’ states #PDAC #ESMO2025 @OncoAlert
➡️68% >|= 2 lines tx
➡️ORR 41%; mPFS 5.6mths
➡️mOS NR; most AEs grade 1/2
➡️ctDNA - high rates KRAS(not~90%), low tumour suppressor rates https://t.co/LNjLxi8HkQ

2

71

24

23

10K

0

5

1

2

3K

Minhua Chu

@chuminhua432

12 months ago

🇨🇳 #GenFleet Therapeutics announced that the latest clinical trial data for its small-molecule KRAS G12D inhibitor, #GFH375, as a monotherapy for NSCLC patients has been selected for #WCLC2025 LBA and a mini-oral presentation. The Phase 1/2 study demonstrated that GFH375 has an overall favorable safety profile in patients with KRAS G12D-mutant solid tumors, with notable efficacy and good safety/tolerability in NSCLC patients. As of July 15 this year, the median follow-up time for 28 NSCLC patients was 4.5 months, with tumor responses observed across multiple dose groups. Among 26 evaluable NSCLC patients, the objective response rate (ORR) was 57.7%, and the disease control rate (DCR) was 88.5%. In the 600 mg QD, the ORR was 68.8%, and the DCR was 93.8%.

1

15

8

4

4K

Minhua Chu

@chuminhua432

about 1 year ago

🇨🇳 #GenFleet Therapeutics’ #HKSE #IPO application has been accepted. https://t.co/XHlpQFIqur Founded in 2017, GenFleet focuses on developing innovative drugs for the treatment of tumors and autoimmune diseases, with RAS as a key focus. Its lead product, a KRAS G12C inhibitor, has been approved for marketing, becoming the first of its MoA drug in China, with domestic commercialization in collaboration with Innovent Biologics. A KRAS G12D inhibitor is about to enter Phase III clinical trials, while a pan-RAS inhibitor and an EGFR antibody-conjugated RAS inhibitor are expected to receive IND approval in the second half of this year. GDF15/IL-6 bispecific antibody entered clinical trials, and a CDK9 inhibitor is set to enter a pivotal clinical trial in the second half of this year. The company’s pipeline also includes TGFβR1 and RIPK1 inhibitors.

chuminhua432's tweet photo. 🇨🇳 #GenFleet Therapeutics’ #HKSE #IPO application has been accepted. https://t.co/XHlpQFIqur

Founded in 2017, GenFleet focuses on developing innovative drugs for the treatment of tumors and autoimmune diseases, with RAS as a key focus.

Its lead product, a KRAS G12C inhibitor, has been approved for marketing, becoming the first of its MoA drug in China, with domestic commercialization in collaboration with Innovent Biologics.

A KRAS G12D inhibitor is about to enter Phase III clinical trials, while a pan-RAS inhibitor and an EGFR antibody-conjugated RAS inhibitor are expected to receive IND approval in the second half of this year.

GDF15/IL-6 bispecific antibody entered clinical trials, and a CDK9 inhibitor is set to enter a pivotal clinical trial in the second half of this year.

The company’s pipeline also includes TGFβR1 and RIPK1 inhibitors.

3

9

2

4

4K

Minhua Chu

@chuminhua432

over 1 year ago

🇨🇳 #GenFleet Therapeutics announced the latest ph2 data of KROCUS study, #fulzerasib (#GFH925, KRAS G12C inhibitor) + cetuximab for 1L NSCLC，in a late-breaking abstract #ELCC2025. https://t.co/IiLLmUkema ORR 80% ，DCR100%. /1

1

3

0

1

878

PharmaShots | Iluminate.Innovate.Inspire @Pharmashot

over 2 years ago

GenFleet Partners with @BeiGeneGlobal to Conduct P-Ib/II Trial of GFH009 and Brukinsa for the Treatment of Diffuse Large B Cell Lymphoma #genfleet #beigene #gfh009 #diffuselargebcelllymphoma #pharma #brukinsa #collaboration #agreement #partnership https://t.co/46aWzd2X7z

Pharmashot's tweet photo. GenFleet Partners with @BeiGeneGlobal to Conduct P-Ib/II Trial of GFH009 and Brukinsa for the Treatment of Diffuse Large B Cell Lymphoma
#genfleet #beigene #gfh009 #diffuselargebcelllymphoma #pharma #brukinsa #collaboration #agreement #partnership
https://t.co/46aWzd2X7z https://t.co/MSPi2rpKrh

0

1

0

147

JanneB @Humanoidiot

about 5 years ago

A strong partnership for GenFleet Therapeutics with Insilico Medicine. #AI #Biotech #GenFleet #Insilico #Drugdiscovery #SearchbySRG https://t.co/WZ0E6OM6Ex

0

2

1

0

Top Tweets for #genfleet

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users